New Research Shows Viability of PET Imaging Agent for Clear Cell Renal Cell Carcinoma
In an interview at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Jeremie Calais, M.D., MSc discussed promising research findings for the use of the positron emission tomography (PET) imaging agent 89ZR-DFO-girentuximab for diagnosing clear cell renal cell carcinoma.
Conventional imaging doesn’t provide sufficient clarity for differentiating between benign renal masses and clear cell renal cell carcinoma (ccRCC), “the deadliest renal cancer and the most frequent one,” noted Jeremie Calais, M.D, MSc, during an interview at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
However, a new positron emission tomography (PET) imaging agent may facilitate more effective detection of ccRCC, according to emerging research from the international multicenter ZIRCON trial. For the ZIRCON study, researchers assessed the use of 89ZR-DFO-girentuximab (TLX250-CDx, Telix Pharmaceuticals) for ccRCC detection in adult patients with indeterminate renal masses. Abdominal PET/computed tomography (CT) imaging was obtained five days after administration of 89ZR-DFO-girentuximab, according to the study.
In a study presented at the SNMMI conference, Dr. Calais discussed findings from the 34-patient University of California Los Angeles (UCLA) cohort of the ZIRCON trial. The study findings revealed an 87 percent sensitivity rate for ccRCC and a 100 percent positive predictive value for positive scans with 89ZR-DFO-girentuximab.
(Editor’s note: For related content, see “Emerging PET/CT Imaging Agent Shows Promise for Diagnosing Clear Cell Renal Cell Carcinoma.”)
“(89ZR-DFO-girentuximab) really provides a great tool for patients with indeterminate mass in the kidney. From seven centimeters to four centimeters and two centimeters, you still keep these good characterization properties. It’s exciting to work with this new imaging agent,” noted Dr. Calais, an associate professor at the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA).
For more insights from Dr. Calais, watch the video below.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
